Adoptive therapy with T cell receptor (TCR)-engineered T cells has demonstrated objective responses in multiple types of tumors, including hard-to-treat solid tumors. To further advance adoptive T cell therapy, it is imperative to counteract deficits in immune control that give way to tumor recurrence. Recurrence of tumor cells is considered a consequence of shortcomings in local CD8 T cell immunity, which in turn is governed by co-stimulatory receptors, such as CD28. In our laboratory, we have designed and tested the therapeutic potential of TCRs equipped with co-stimulatory molecules. These new TCRs provide T cells with the unique ability to activate distinct immune activation and transcriptional programs and demonstrate significant delays in tumor recurrence in immune-competent, tumor-bearing mice.

In the current project, we will study changes in T cell signaling, transcriptomics, energetics as well as immune micro-environments as a consequence of these co-stimulatory TCRs using in silico, in vitro and in vivo models and tools. Aims of this project include: (1) definition of key parameters downstream of T cell co-stimulation that determine effective anti-tumor T cell responses; (2) selection and testing combination therapy with co-stimulatory TCRs; and (3) validation of therapeutic value of co-stimulatory TCRs towards human cancers.

You have obtained your PhD in the field of Immunology, preferably T Cell Immunology, you are familiar with preclinical T cell and TCR-based studies. You are able to coordinate and supervise research tasks, able to acquire research funds, and are highly motivated to perform research, take initiatives, communicate easily and cooperate in a team of researchers.

Being able to present a certificate of good conduct, a valid proof of identity, diploma's and/ or relevant registration such as BIG/RGS are conditions for the appointment.

We offer a temporary position for 3 years. The gross monthly salary amounts to a maximum of € 4.481,- (scale 10), depending on your level of education and relevant experience and based on a full-time working week of 36 hours. The terms of employment are in accordance with the Collective Bargaining Agreement for University Medical Centers (CAO UMC).

Erasmus MC

Erasmus MC stands for a healthy population and excellence in healthcare. By conducting groundbreaking work, we aim to push boundaries through leading the way in research, education and healthcare. We have access to the latest equipment and techniques in a state-of-the-art environment.

The Department of Medical Oncology has a long-standing tradition in clinical and translational cancer research. The research activities of our department are organized into 5 different divisions: Translational Cancer Genomics and Proteomics, Translational Pharmacology; Translational Onco-Immunology; Clinical Trials; and Palliative and Supportive Care. Research at the laboratory of Tumor Immunology (Division of Translational Onco-Immunology) is involved in the following activities towards new or ongoing patient studies: development and implemention of adoptive T cell treatment; understanding and intervening with cross-talk between tumor cells and micro-environment; and immune monitoring of T cell phenotype and function in patient cohorts.